



David Segarnick Ph.D., Managing Director, heads BERYL China's Healthcare Division. At Beryl, he is also involved in manager due diligence. He provides Beryl analysts with evaluation pertaining to specific healthcare, pharmaceutical and biotech holdings in hedge funds' portfolios. Dr. Segarnick has been a medical and marketing authority in healthcare communications and education for more than 20 years. He held senior management and strategic planning positions in industry and academia. He has extensive pharmaceutical pre-launch and launch product development experience in major therapeutic areas. His specific areas of expertise include anesthesiology, anti-infectives, cardiovascular disease, chronic pain, endocrinology/diabetology, gastroenterology, hematology, men's health, obstetrics/gynecology, oncology, orthopedics, rheumatology, neurology, and psychiatry.

Dr. Segarnick has worked on many of the major blockbuster product launches over the past two decades. He is the architect of numerous scientific platforms underlying clinical differentiation for pharmaceutical and biotech product introductions worldwide. He trained at the New York University School of Medicine and the New York Veterans Affairs Medical Center. He was a member of the faculty at the New York University School of Medicine, Bellevue Hospital, and the New York Veterans Administration Medical Center. He moderates more than 20 advisory board meetings, clinical development workshops and scientific platform development programs each year and provides onsite data surveillance at key international medical congresses. Dr. Segarnick has authored more than a dozen articles in peer-reviewed medical journals and has contributed several chapters in medical textbooks. He currently teaches pharmacology and product development to medical and graduate students at the University of Medicine & Dentistry of New Jersey in Newark.

Contact: david@berylconsulting.com